Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Eledon Pharmaceuticals in a report issued on Wednesday, June 18th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.31) for the quarter. HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals' Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($0.97) EPS and FY2026 earnings at ($1.20) EPS.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.20.
Separately, Wall Street Zen cut Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, June 6th.
Check Out Our Latest Stock Report on Eledon Pharmaceuticals
Eledon Pharmaceuticals Trading Up 0.4%
ELDN stock traded up $0.01 during trading hours on Monday, hitting $2.75. 328,524 shares of the stock traded hands, compared to its average volume of 278,273. The stock has a 50-day simple moving average of $3.01 and a 200 day simple moving average of $3.65. Eledon Pharmaceuticals has a one year low of $2.30 and a one year high of $5.54. The company has a market cap of $164.67 million, a P/E ratio of -1.31 and a beta of -0.17.
Hedge Funds Weigh In On Eledon Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the stock. Siren L.L.C. purchased a new position in Eledon Pharmaceuticals in the 1st quarter worth about $2,340,000. Jane Street Group LLC increased its stake in Eledon Pharmaceuticals by 83.7% in the 1st quarter. Jane Street Group LLC now owns 224,600 shares of the company's stock worth $761,000 after purchasing an additional 102,325 shares in the last quarter. Zimmer Partners LP increased its stake in Eledon Pharmaceuticals by 0.7% in the 1st quarter. Zimmer Partners LP now owns 754,970 shares of the company's stock worth $2,559,000 after purchasing an additional 4,970 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Eledon Pharmaceuticals by 78.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 258,106 shares of the company's stock worth $875,000 after purchasing an additional 113,261 shares in the last quarter. Finally, 22NW LP purchased a new position in Eledon Pharmaceuticals in the 1st quarter worth about $2,157,000. Hedge funds and other institutional investors own 56.77% of the company's stock.
Eledon Pharmaceuticals Company Profile
(
Get Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Stories
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
